|
|
|
| home > ebr > winter 2022 > biomaterials: challenges, characteristics, and considerations |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
EBR: What is the role of biomaterials in biopharmaceutical and biomedical applications?
Dr Jeff Daelman: Biomaterials restore function and facilitate healing after injury or disease, and are used in applications including medical implants, tissue regeneration, molecular probes, wound dressings, and biosensors. They provide a physical structure that can be used as a drug delivery system for active pharmaceutical ingredients or other ingredients, or as a scaffold to which cells can attach. However, with such a diverse range of uses, the specific role of biomaterials is application-dependent.
Biomaterials can be natural or synthetic. For cellular applications, such as tissue engineering, we need to consider that the majority of the cells in our body are attached or anchored to an extracellular matrix (ECM). So, ECM-derived biomaterials – such as collagen and its denatured counterpart (gelatin) – can enhance the attachment and migration of cells promoting tissue repair. For that reason, collagen and other natural biomaterials are an ideal starting material thanks to the fact that they are well tolerated, promoting cellular adhesion and subsequent tissue formation to facilitate body integration, while their biodegradability allows for tissue remodelling. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Clinical trial platform provider encapsia welcomes new COO
Horsham, United Kingdom, 5th January 2023: Clinical trial
management solutions provider, encapsia, has announced the appointment
of Francis Destin as its new Chief Operating Officer. Francis brings
more than 20 years of expertise to the role, specialising in the
management of data-related projects in clinical trials and statistical
analysis software. His adoption of a future-facing approach to clinical
research supports encapsia’s vision of transforming clinical trials for
the benefit of the biotech, pharma and biopharma industries.
More info >> |
|
 |
White Papers |
 |
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
RSSL
Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >> |
|
|
